Rameda’s profits jump by 101.1% in 1H 2022
Expansion in NPM was driven by growing operating profitability coupled with decreasing…
Rameda acquires pharmaceutical drug expected to contribute EGP 30m to revenues
The company said that it will benefit from the growth factors that…
IFC partners with Rameda to ‘green’ its operations in Egypt
In a Tuesday press statement the IFC said that through this partnership,…
Rameda begins production of coronavirus antiviral drug ‘Molnupiravir Rameda’
The drug was developed by the American company Merck and is an…
Rameda’s new antiviral medication successfully opens up new export markets
Levant region has lion’s share of group’s export volumes in Q1 2021
Rameda for pharmaceuticals expects COVID-19 to continue until H1 of 2022
Company plans to launch 8-10 products in 2021, eyes entry in new…
Rameda posts neutral results with revenues of EGP 205m
Revenues reflect downturn of 11.8% q-o-q, but rise of 5.6% y-o-y
Rameda gets EDA approval to price two coronavirus medicines
Rameda started last month manufacturing Anviziram, which contains the active pharmaceutical ingredient…
Rameda receives export requests for its COVID-19 drug Anviziram
The pharmaceuticals firm awaits the Egyptian Ministry of Health’s approval to export…
Rameda starts manufacturing of generic Anviziram for COVID-19 treatment
EDA also grants approval for Rameda to begin manufacturing intravenous Remedisivir vials